leer
leer
leer
DeutschEnglishImprint
navifuellAbout usleerTechnology PlatformleerProduct PipelineleerHow to PartnerleerInvestor RelationsleerNewsleerContactleer
linie
leer
leer
Strategy
Management
Supervisory Board
External Partners

 

bildmotiv1
Motivpunkte
leer
leer

Bernhard Günther Dipl.-Ing. (FH)
Managing Director/Chief Executive Officer

Bernhard Günther joined Novaliq as Chief Executive Officer in January 2007. He has more than 20 years of experience in the field of biopharmaceutics and medical devices. Prior to Novaliq, Mr. Günther served as Chief Executive Officer of Fluoron GmbH, a German medical device company, which pioneered the development of ophthalmic implants based on semifluorinated alkanes for the treatment of serious retinal diseases.

During his tenure at Fluoron, Mr. Günther was also responsible for the successful development and launch of the long-term endotamponade Densiron® 68 and the intraocular staining solution Brilliant Peel® as well. Mr. Günther was for 10 years the Head of Regulatory Affairs and Managing Director for Marketing and Sales at Geuder AG, a leading ophthalmosurgical company in Germany. He also served as a member on the Board of Fluoron GmbH. Mr. Günther holds a Diploma in Polymer Engineering from the University of Applied Sciences in Darmstadt, Germany.


Oliver Schlüter Ph.D.
Managing Director/Chief Financial Officer

Previously, Dr. Schlüter was CFO of CureVac GmbH. During his tenure at CureVac, he was vital to the transformation of the 70 employee R&D-driven company to a 170 employee customer centric and value focused corporation with several strategic partnerships and in-house cGMP-manufacturing.

Since his appointment in 2010, the company secured more than €200 million in funding and increased the company value more than tenfold to more than €1 billion. Dr. Schlüter has 20 years of professional experience within Finance and Life Sciences.  He holds a PhD in computational finance and studied business administration.


Hartmut Voss Ph.D.
Chief Business Officer

Dr. Voss has 30 years of experience within Life Sciences and has spent more than 15 years as an entrepreneur, holding various senior management positions within the Biotechnology Industry. He is responsible for the scientific evaluation of biotechnology and biopharmaceutical companies at dievini Hopp BioTech holding GmbH & Co. KG.

Following his studies in biology at the University of Kaiserslautern,Dr. Voss obtained his PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. In 1997, he co-founded LION bioscience AG (now SYGNIS Pharma AG) and in 2004, Life Biosystems GmbH (now Molecular Health AG), where he held various senior management positions.


Frank Löscher Ph.D.
Chief Technology Officer

Dr. Frank Löscher joined Novaliq in February 2014. His 20 years of experience in the pharmaceutical industry covers the gamut from active ingredient chemistry to pharmaceutical process development and manufacturing.  In the last 10 years he collected additional experiences in the areas of Business Development and licensing.

As part of the executive board Dr. Löscher is responsible for the areas of Research, Development and commercial production. He graduated as Chemist at Ruprecht Karls University in Heidelberg and later received his Ph.D. in Biophysical Chemistry at the University of Regensburg.


leer © 2016 Novaliq GmbH Germany. All rights reserved.